Vassiliou Alice G, Kotanidou Anastasia, Mastora Zafeiria, Tascini Carlo, Cardinali Gianluigi, Orfanos Stylianos E
First Department of Critical Care Medicine and Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Medical School of the National and Kapodistrian University of Athens, Athens, Greece.
Infect Dis Ther. 2018 Mar;7(Suppl 1):3-14. doi: 10.1007/s40121-018-0193-2. Epub 2018 Mar 16.
A soluble (s) form of the endothelial protein C receptor (EPCR) circulates in plasma and inhibits activated protein C (APC) activities. The clinical impact of sEPCR and its involvement in the septic process is under investigation. This study determined the frequencies of EPCR haplotypes H1 and H3 to investigate possible associations with plasma admission levels of sEPCR in an intensive care unit (ICU) cohort of septic patients.
Three polymorphisms in the EPCR gene were genotyped in 239 Caucasian critically ill patients, and their plasma sEPCR levels were also measured at the time of admission to the ICU. Multivariate logistic regression analysis controlling for sepsis severity, age, acute physiology and chronic health evaluation (APACHE II) and sequential organ failure assessment (SOFA) scores, lactate level, sex, diagnostic category, length of ICU stay and hospital mortality was performed to determine the effect of EPCR haplotypes H1 and H3 on the levels of sEPCR.
Individuals carrying at least one H3 allele had significantly higher levels of sEPCR than individuals with no H3 alleles (p < 0.001). No differences were found in the distribution of the H3 allele in the patient groups categorized using the pre-existing and current sepsis-3 definitions.
Using the preceding and current sepsis definitions, sEPCR levels and the H3 haplotype were not associated with sepsis severity and the risk of poor outcomes in septic patients; however, the EPCR H3 allele contributed to higher levels of sEPCR.
内皮蛋白C受体(EPCR)的可溶性(s)形式在血浆中循环,并抑制活化蛋白C(APC)的活性。可溶性EPCR的临床影响及其在脓毒症过程中的作用正在研究中。本研究确定了EPCR单倍型H1和H3的频率,以调查脓毒症患者重症监护病房(ICU)队列中可溶性EPCR血浆入院水平的可能关联。
对239名白种人重症患者的EPCR基因中的三个多态性进行基因分型,并在其入住ICU时测量血浆可溶性EPCR水平。进行多因素逻辑回归分析,控制脓毒症严重程度、年龄、急性生理学和慢性健康状况评估(APACHE II)以及序贯器官衰竭评估(SOFA)评分、乳酸水平、性别、诊断类别、ICU住院时间和医院死亡率,以确定EPCR单倍型H1和H3对可溶性EPCR水平的影响。
携带至少一个H3等位基因的个体的可溶性EPCR水平显著高于无H3等位基因的个体(p<0.001)。在使用先前和当前脓毒症-3定义分类的患者组中,H3等位基因的分布没有差异。
使用先前和当前的脓毒症定义,可溶性EPCR水平和H3单倍型与脓毒症患者的脓毒症严重程度和不良结局风险无关;然而,EPCR H3等位基因导致更高水平的可溶性EPCR。